UmaMadhavBorateMD

Oncology • Columbus, OH

Hematologic Oncology

Assistant Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Dr. Borate is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Borate's full profile

Already have an account?

Office
460 W 10th Ave
# L586
Columbus, OH 43210
Phone+1 614-293-9869

Education & Training

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2004 - 2008
B.J. Medical College - University of PuneClass of 2003

Certifications & Licensure

OH State Medical License 2020 - 2026
OR State Medical License 2016 - 2023
AL State Medical License 2008 - 2016
PA State Medical License 2004 - 2008
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
A Safety Study of SGN-CD19A for Leukemia and Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01
Recruiting
Phase 1, Phase 2
Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Aug 16
Active, not recruiting
Phase 1
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Start of enrollment: 2019 Feb 20
Recruiting
Phase 1, Phase 2
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Start of enrollment: 2019 Mar 13
Suspended
Phase 1
Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Start of enrollment: 2022 Jun 23
Recruiting
Phase 2
Roles: Contact, Sponsor-Investigator, Principal Investigator
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Start of enrollment: 2024 Feb 20
Recruiting
Phase 1
Roles: Sponsor-Investigator
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) Start of enrollment: 2024 Jul 15
Not yet recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

312 citations
Proteogenomic and metabolomic characterization of human glioblastoma
Liang-Bo Wang, Alla Karpova, Marina A. Gritsenko, Jennifer E. Kyle, Song Cao
Cancer Cell. 2021-04-12
7 citations
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelod...
Andrew M Brunner, Jordi Esteve, Kimmo Porkka, Steve Knapper, Elie Traer
American Journal of Hematology. 2024-02-01
46 citations
Nonbiological factors affecting survival in younger patients with acute myeloid leukemia
Uma Borate, Shin Mineishi, Luciano J. Costa
Cancer. 2015-11-01

Journal Articles

Functional Genomic Landscape of Acute Myeloid Leukaemia
Marc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature

Abstracts/Posters

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Framework to Identify and Prioritize Candidate Inherited Myeloid Malignancy Germline Variants Leveraging the BEAT AML Cohort
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
Uma Borate, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
RGL4 over Expression Correlates with Variation in Midostaurin Response in FLT3-ITD Mutant AML Samples
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
IDH Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Targeted Therapy in Leukemia
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

Identification of Targeted Therapies for Rare Adult Mature T-cell Leukemia Using Functional Ex Vivo Screening of Primary Patient SamplesFebruary 9th, 2017
Social Factors Affect Leukemia SurvivalSeptember 14th, 2015